Summit Therapeutics plc Holding(s) In Company
January 10 2019 - 6:30AM
UK Regulatory
TIDMSUMM
TR-1: Standard form for notification of major holdings
NOTIFICATION OF MAJOR HOLDINGS (to be sent to the
relevant issuer and to the FCA in Microsoft Word format
if possible)(i)
-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
1a. Identity of the issuer or the underlying issuer
of existing shares to which voting rights are attached(ii)
: Summit Therapeutics plc
--------------------------------------------------------------------------------------------------------- ------------------------------------------------------------------------------------------------------------------
1b. Please indicate if the issuer is a non-UK issuer
(please mark with an "X" if appropriate)
-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
Non-UK issuer
------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- --------------------------------------------
2. Reason for the notification (please mark the appropriate
box or boxes with an "X")
-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
An acquisition or disposal of voting rights X
------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- --------------------------------------------
An acquisition or disposal of financial instruments
------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- --------------------------------------------
An event changing the breakdown of voting rights X
------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- --------------------------------------------
Other (please specify)(iii) :
------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- --------------------------------------------
3. Details of person subject to the notification obligation(iv)
Name Chelverton Asset Management Limited
City and country of registered office (if applicable) Bath, United Kingdom
4. Full name of shareholder(s) (if different from
3.)(v)
-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
Name Northern Trust CI01
--------------------------------------------------------------------------------------------------------- ------------------------------------------------------------------------------------------------------------------
City and country of registered office (if applicable)
--------------------------------------------------------------------------------------------------------- ------------------------------------------------------------------------------------------------------------------
5. Date on which the threshold was crossed or reached(vi)
: 9 January 2019
--------------------------------------------------------------------------------------------------------- ------------------------------------------------------------------------------------------------------------------
6. Date on which issuer notified (DD/MM/YYYY): 10 January 2019
--------------------------------------------------------------------------------------------------------- ------------------------------------------------------------------------------------------------------------------
7. Total positions of person(s) subject to the notification
obligation
-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
% of voting rights attached to shares (total of 8. % of voting rights through financial instruments Total of both in %
A) (total of 8.B 1 + 8.B 2) (8.A + 8.B) Total number of voting rights of issuer(vii)
--------------------------------------------------- ---------------------------------------------------- ------------------------------------------------ ------------------ --------------------------------------------
Resulting situation on the date on which threshold
was crossed or reached 2.81% 2.81% 160,389,881
--------------------------------------------------- ------------------- ------------------------------ ------------------------------------------------ ----- ---------- --------------------------------------------
Position of previous notification (if
applicable) 5.17%
--------------------------------------------------- ------------------- ------------------------------ ------------------------------------------------ ------------------ --------------------------------------------
8. Notified details of the resulting situation on
the date on which the threshold was crossed or reached(viii)
---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
A: Voting rights attached to shares
---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
Number of voting rights(ix) % of voting rights
-------------------------
Class/type of
shares Direct Indirect Direct Indirect
ISIN code (if possible) (Art 9 of Directive 2004/109/EC) (DTR5.1) (Art 10 of Directive 2004/109/EC) (DTR5.2.1) (Art 9 of Directive 2004/109/EC) (DTR5.1) (Art 10 of Directive 2004/109/EC) (DTR5.2.1)
-------------------------- ------------------------------------------ --------------------------------------------- ----------------------------------------------------- ---------------------------------------------
Common Stock GBp1
GB00BN40HZ01 4,500,000 2.81%
-------------------------- ------------------------------------------ --------------------------------------------- --------------------- ----------------------------- ---------------------------------------------
SUBTOTAL 8. A 4,500,000 2.81%
-------------------------- ----------------------------------------------------------------------------------------- ----------------------------------------------------- --------------------------------------------
B 1: Financial Instruments according to Art. 13(1)(a)
of Directive 2004/109/EC (DTR5.3.1.1 (a))
---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
Type of financial Expiration Exercise/ Number of voting rights that may be acquired if the % of voting rights
instrument date(x) Conversion Period(xi) instrument is
exercised/converted.
-------------------------- ------------------------------------------ --------------------------------------------- ----------------------------------------------------- ---------------------------------------------
SUBTOTAL 8. B 1
--------------------------------------------- ----------------------------------------------------- ---------------------------------------------
B 2: Financial Instruments with similar economic effect
according to Art. 13(1)(b) of Directive 2004/109/EC
(DTR5.3.1.1 (b))
---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
Type of financial Expiration Exercise/ Conversion Physical or cash Number of voting rights % of voting rights
instrument date(x) Period (xi) settlement(xii)
------------------------- ------------------------------------------- --------------------------------------------- --------------------- ------------------------------ ---------------------------------------------
SUBTOTAL 8.B.2
--------------------- ------------------------------ ---------------------------------------------
9. Information in relation to the person subject to
the notification obligation (please mark the
applicable box with an "X")
Person subject to the notification obligation is not
controlled by any natural person or legal entity and
does not control any other undertaking(s) holding
directly or indirectly an interest in the (underlying)
issuer(xiii)
Full chain of controlled undertakings through which X
the voting rights and/or the
financial instruments are effectively held starting
with the ultimate controlling natural person or legal
entity(xiv) (please add additional rows as necessary)
---------------------------------------------------------------------------------------------------------------------- -----------------------------------------------------------
Name(xv) % of voting rights if it equals or is higher than % of voting rights through financial instruments if Total of both if it equals or is higher than the notifiable
the notifiable threshold it equals or is higher than the notifiable threshold threshold
---------- ------------------------------------------------- ----------------------------------------------------- -------------------------------------------------------------
David,
Mary,
Thomas and
Harry
Horner
---------- ------------------------------------------------- ----------------------------------------------------- -------------------------------------------------------------
Chelverton
Asset
Management
Holdings
Limited
---------- ------------------------------------------------- ----------------------------------------------------- -------------------------------------------------------------
Chelverton
Asset
Management
Limited
---------- ------------------------------------------------- ----------------------------------------------------- -------------------------------------------------------------
10. In case of proxy voting, please identify:
-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
Name of the proxy holder
------------------------------------------------------------- --------------------------------------------------------------------------------------------------------------------
The number and % of voting rights held
------------------------------------------------------------- --------------------------------------------------------------------------------------------------------------------
The date until which the voting rights will be held
------------------------------------------------------------- --------------------------------------------------------------------------------------------------------------------
11. Additional information(xvi)
-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
Place of completion Chelmsford, United Kingdom
------------------- --------------------------
Date of completion 10 January 2019
------------------- --------------------------
(END) Dow Jones Newswires
January 10, 2019 06:30 ET (11:30 GMT)
Copyright (c) 2019 Dow Jones & Company, Inc.
Summit Therapeutics (LSE:SUMM)
Historical Stock Chart
From May 2024 to Jun 2024
Summit Therapeutics (LSE:SUMM)
Historical Stock Chart
From Jun 2023 to Jun 2024